Earnix Appoints Erez Barak as Chief Technology Officer
10.9.2023 09:00:00 EEST | Business Wire | Press release
Earnix, the global provider of intelligent SaaS solutions for insurers and banks, today announced the appointment of Erez Barak to Chief Technology Officer (CTO) effective September 10. Erez will helm Earnix’s research and development (R&D) and analytics teams. He is a seasoned technology executive with more than 22 years of experience including leadership roles at tech giants Microsoft and HP.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230909531291/en/
Erez Barak has been appointed CTO of Earnix, the global provider of intelligent, composable, SaaS solutions for insurers and banks. (Photo: Business Wire)
His passion for solving business problems through innovative technologies and engaging product experiences is rooted in his diverse background, including cloud infrastructure, big data systems, AI systems, developer platforms, enterprise productivity and marketing systems. He has held engineering and product roles at Optify (acquired by Marketo), and Mercury Interactive. Most recently, Erez was General Manager and Vice President of Engineering at Sumo Logic, a machine data analytics, operations, and business intelligence company.
“Erez will lead the Analytics and R&D teams at Earnix, as they evolve the platform and broaden our capabilities. With a focus on customer value delivery, he will lead technology development and advancement,” said Robin Gilthorpe, CEO, Earnix. “Erez is well-suited to deliver on our commitments to accelerated innovation and the operational application of AI at scale.”
As part of Earnix’s upcoming global Eˣcelerate Summit, Erez will address hundreds of insurance executives on driving enterprise value with AI and analytics. For more information on his presentation and to view a full event agenda, click here.
“I am thrilled to take the lead of Earnix’s R&D and analytics teams at this pivotal time in the financial services market,” said Erez Barak, incoming CTO at Earnix. “Earnix offers a unique combination of top talent, best-in-class technology, and close customer engagement. These building blocks, and its pioneering spirit, will be key to building a world class platform that delivers meaningful value to Earnix’s customers globally.”
About Earnix
Earnix is the premier provider of mission-critical cloud-based intelligent solutions across pricing, rating, underwriting, product personalization and telematics. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. It has been innovating for insurers and banks since 2001 with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel.
For more information please visit: earnix.com.
Connect with Earnix via Twitter, LinkedIn and Facebook. Read the Earnix Blog.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230909531291/en/
Contact information
Jena Murphy
jena.murphy@earnix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. In DESTINY-Breast09, Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% versus a taxan
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 09:30:00 EEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
ADM Club Digitises the Renaissance Court Model Through a Bespoke Technology Stack for Independent Luxury and High Affinity Audiences1.9.2026 09:08:00 EEST | Press release
Alessia Demetz, Founder & CEO of Alesya de Monaco LTD, headquartered in London and the Principality of Monaco, created ADM Club – a business model built on a vertical digital architecture and designed for global scalability – operating at the intersection of luxury craftsmanship and an international network of high-net-worth connoisseurs. This powerful, disruptive vision — bringing hyper-curated craft direct to the customer — translates into digital form the role once played by patrons within Renaissance courts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821319838/en/ Credits: Photo courtesy of ADM Club. Photography by Martin Morrell. Designed from the outset to enable the model to scale, this architecture supports both the development of the ADM Club network and deployment with international partners, opening the way to collaborations with operators and organisations that reach high-spending audiences. ADM Club is no
Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 09:00:00 EEST | Press release
Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize critical infrastructure, this partnership provides a scalable and reliable framework for implementing intelligent street lighting systems that reduce ener
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom